European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, MyelomaMarch 31, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, MyelomaJanuary 30, 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020